2013年4月10日,来自美国化学会新奥尔良(New Orleans)会议的信息,首次透露了5种药物候选者的结构式,它们分别转载如下(见下图),因为每一种药物候选者均已经申请了专利,有些还不止一项专利,而是多项专利,而且已经列出了专利号,通过GOOGLE 搜索均可以得到相关专利文献,如利用 世界知识产权组织网 也可以得到。下面的5种化合物,每一种均已经有一项专利文件(红色字体)可以直接点击即可下载。尽管并非每一种药物候选者最终都有可能成为可以用于临床,而且真正成为药物的概率很低,但是了解其相关信息或许对于新药研发有所帮助和启发。 BMS-906024 Company: Bristol-Myers Squibb Meant to treat: cancers including breast, lung, colon, and leukemia Mode of action: pan-Notch inhibitor Medicinal chemistry tidbit: The BMS team used an oxidative enolate heterocoupling en route to the candidate– a procedure from Phil Baran’s lab at Scripps Research Institute. JACS 130, 11546 Status in the pipeline: Phase I Relevant documents: WO 2012/129353 LGX818 Company: Novartis Institutes for Biomedical Research and Genomics Institute of the Novartis Research Foundation Meant to treat: melanoma with a specific mutation in B-RAF kinase: V600E Mode of action: selective mutant B-RAF kinase inhibitor Status in the pipeline: Phase Ib/II Relevant documents: WO 2011/023773 ; WO 2011/025927 AZD5423 Company: AstraZeneca Meant to treat: respiratory diseases, in particular chronic obstructive pulmonary disease Mode of action: non-steroidal glucocorticoid receptor modulators Medicinal chemistry tidbit: This compound originated in part from a collaboration with Bayer Pharma. Status in the pipeline: Phase II Relevant documents: WO 2011/061527 ; WO 2010/008341 ; WO 2009/142568 Birinapant (formerly known as TL32711) Company: TetraLogic Pharmaceuticals Meant to treat: cancer Mode of action: blocks the inhibitor of apoptosis proteins to reinstate cancer cell death Status in the pipeline: Phase II Relevant documents: US 8,283,372 MGL-3196 (previously VIA-3196) Company: Madrigal Pharmaceuticals, acquired from VIA Pharmaceuticals, licensed from Roche Meant to treat: high cholesterol/high triglycerides Mode of action: mimics thyroid hormone, targeted to thyroid hormone receptor beta in the liver Medicinal chemistry tidbit: this molecule was discovered at Roche’s now-shuttered Nutley site. Status in the pipeline: completed Phase I trials Relevant documents: WO 2007/009913 ; WO 2009/03717